

# National Board of Examinations

**Question Paper Name :** DrNB Clinical Hematology Paper3

**Is this Group for Examiner? :** No

**Enable Mark as Answered Mark for Review and Clear Response :** Yes

## **Question Number : 1 Question Type : SUBJECTIVE**

- a) Write a brief note on the "update" in molecular diagnosis and prognostication of B- Acute Lymphoblastic Leukemia (B-ALL) not otherwise specified. [5]
- b) Describe the immunophenotype and cytogenetics in the diagnosis of Mixed phenotype acute leukemia. [5]

## **Question Number : 2 Question Type : SUBJECTIVE**

- a) Enumerate the challenges of Minimal residual disease testing in myeloma patients on Daratumumab. [3]
- b) Compare the role of PET/CT and Flowcytometric MRD analysis for therapeutic monitoring in Myeloma. [3]
- c) Enumerate the advantages and disadvantages of monoclonal antibodies in newly diagnosed multiple myeloma (NDMM). [4]

## **Question Number : 3 Question Type : SUBJECTIVE**

- a) Write a brief note on Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) and near ETP ALL. [5]
- b) Highlight the recent avances in the managment of relapsed T-ALL. [5]

## **Question Number : 4 Question Type : SUBJECTIVE**

- a) Classify Hodgkin's lymphoma. [3]
- b) Discuss the role of PET in classical HL. [3]
- c) Outline the management strategies for relapsed classical HL. [4]

**Question Number : 5 Question Type : SUBJECTIVE**

- a) Describe the role of TP53 mutation and IGHV mutational status testing in CLL. [5]
- b) Describe the incorporation of the newer therapeutics in management of CLL. [5]

**Question Number : 6 Question Type : SUBJECTIVE**

A 47-year-old male with cerebral venous sinus thrombosis was found to have a PNH clone and a moderately hypocellular bone marrow

- a) What is the pathogenesis of thrombosis in PNH? [3]
- b) What is the mechanism of action of monoclonal antibodies used in this condition? [2]
- c) What will be your management approach to this patient? [5]

**Question Number : 7 Question Type : SUBJECTIVE**

- a) Write a note on inhibitor testing in hemophilia A. [5]
- b) Discuss the role of non factor based therapy in hemophilia A. [5]

**Question Number : 8 Question Type : SUBJECTIVE**

- a) Describe clinical manifestations of Sezary syndrome and its diagnostic criteria. [5]
- b) Write a note on management of cutaneous lymphomas. [5]

**Question Number : 9 Question Type : SUBJECTIVE**

- a) Enumerate salient points of Bellini trial and its outcome. [4]
- b) Describe utility of Venetoclax in haemato-lymphoid neoplasms. [6]

**Question Number : 10 Question Type : SUBJECTIVE**

- a) What is Split chimerism? [3]
- b) Describe the various methods for Chimerism testing. [4]
- c) Discuss the optimal utilisation of chimerism testing in hematopoietic stem cell transplantation

(HSCT). [3]